Sanofi CFO says won't be affected by Novo's Catalent deal

Reuters
2024-10-25

FRANKFURT, Oct 25 (Reuters) - Sanofi's finance chief on Friday said the company won't be affected by Novo Nordisk's controlling shareholder's decision to acquire contract drug manufacturer Catalent , adding the deal made sense for its rival.

"They desperately need capacity so it makes sense for them," Sanofi CFO Francois-Xavier Roger said in a media call after the release of third-quarter results.

He added Novo paid a "very heavy price to get access to the capacity", given very strong demand for weight-loss drugs.

Swiss drugmaker Roche on Wednesday joined peer Eli Lilly in voicing concern over the planned Catalent takeover, saying it could hit competition in the booming weight-loss drug industry.

(Reporting by Ludwig Burger)

((ludwig.burger@thomsonreuters.com; +49 30 220133634;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10